TeleMAb Retrospective Cohort Study (NCT07405294) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
TeleMAb Retrospective Cohort Study
United States400 participantsStarted 2023-06-12
Plain-language summary
The objective of this study is to evaluate whether there are different clinical outcomes and unscheduled follow-ups between in-person and telemedicine medication abortion, and to better understand patients' experiences with telemedicine medication abortion and their motivations for seeking unscheduled follow-up care in a setting where abortion care, including both virtual and in-person follow-up care, is readily accessible.
Who can participate
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Received telemedicine or in-person medication abortion at Columbia University Irving Medical Center's associated practices from June 12, 2023 through September 30, 2024
* Gestational age \<70 days (based on best obstetrical dating)
* English or Spanish speaking
Exclusion Criteria:
* Received mifepristone and misoprostol for early pregnancy loss
* Patient determined to have contraindication to medication abortion
* Opted for procedural management instead of medication abortion
* Decided to continue with the pregnancy
* Presenting for a second medication abortion at CUIMC during the study period
* Non-English or Spanish speaking
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study is looking back at records of people who had medication abortions through telemedicine — since it's a retrospective study and not a treatment trial, how might its findings about unscheduled follow-up visits be relevant to my own care if I'm considering medication abortion via telemedicine?
2Since this study is no longer enrolling participants, are there any published or preliminary results about how often patients needed unscheduled follow-ups after telemedicine-based medication abortion, and what that might mean for what to expect during my own care?
3How does getting a medication abortion through telemedicine compare to an in-person clinic visit in terms of safety monitoring and access to follow-up care if something unexpected comes up?
4If unscheduled follow-ups are one of the main things being tracked in this study, what kinds of situations most commonly lead to those extra visits after a medication abortion, and how would we handle one if it happened in my case?
5Are there circumstances — like my health history or where I live — that might make in-person care a better fit for me than a telemedicine approach to medication abortion, based on what studies like this one are finding?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.